Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Investment

Alexion signs immune-system development pacts with Affibody and Zealand Pharma

by Ryan Cross
March 29, 2019 | A version of this story appeared in Volume 97, Issue 13

 

Alexion Pharmaceuticals has struck two new partnerships to develop biologic drugs that can be administered subcutaneously for immune system diseases. Alexion will pay Affibody $25 million to codevelop an antibody-like protein therapy for IgG-mediated autoimmune conditions. Separately, Alexion will pay Zealand Pharma $25 million and make a $15 million investment in the firm toward peptide therapies for diseases related to the innate immune system. Affibody and Zealand both could earn more than $600 million in milestone payments if the therapies are successful.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.